Western Union Collaborates with Leading French Fintech Linxo to Launch Digital Money Transfers
29.6.2021 14:27:00 EEST | Business Wire | Press release
Western Union, a leader in cross-border, cross-currency money movement and payments, has collaborated with Linxo, a leading budget management and bank account aggregation application in France, to enable users to make local and cross-border payments through Western Union’s platform.
Linxo’s customers can now make and manage money transfers through Western Union’s platform, quickly, conveniently, and reliably, 24/7. Users can fund their transfers through their bank account or card, and have their funds paid out into billions of bank accounts and millions of mobile wallets in approximately 125 countries, or more than half a million retail locations in more than 200 countries and territories.
“We are pleased to be joining forces with Linxo, offering the 3.5 million users of this innovative app access to the broadest digital global network coverage within the cross-border person-to-person payment sector,” said Massimiliano Alvisini, Head of Europe, CIS, and Africa Network at Western Union. “In France, and across the world, we partner with fintechs, banks and post offices, offering their customers flexibility and trust underpinned by technology, customer experience and compliance,” he said.
Established in 2010, Linxo is a pioneering account aggregation fintech, that optimizes bank account and transaction management for its users. The Linxo application is available in both free and premium versions on the Apple App Store and on Google Play.
“By integrating the Western Union platform into our Linxo Marketplace, we are providing our users with a new and seamless customer experience thanks to enhanced functionalities for the management of their financial assets from a single space: consultation and management of accounts, sending or transferring money to their families and loved ones,” comments Bruno Van Haetsdaele, CEO and Co-Founder of Linxo Group. “Our ambition was to create a virtuous and open ecosystem. With the integration of the Western Union platform, this is now a reality. And we will continue to integrate new value-added services to provide our users with a quality service that exceeds their expectations within the Linxo application.”
About Western Union
The Western Union Company (NYSE: WU) is a global leader in cross-border, cross-currency money movement and payments. Western Union’s platform provides seamless cross-border flows, and its leading global financial network bridges more than 200 countries and territories and over 130 currencies. We connect businesses, financial institutions, governments, and consumers through one of the world’s widest reaching networks, accessing billions of bank accounts, millions of digital wallets and cards, and over half a million-retail locations. Western Union connects the world to bring boundless possibilities within reach. For more information, visit www.westernunion.com
About Linxo
Linxo Group is a subsidiary of Crédit Agricole Payment Services, which {harnesses} Crédit Agricole Group’s expertise in marketing, innovation, processing and interbank representation. Since 2010, Linxo Group has been developing and marketing solutions for account aggregation, payment initiation and personal finance management.
The platform of its subsidiary Oxlin, a payment institution authorised by the ACPR [French Prudential Supervision and Resolution Authority], provides all the technology to access banking data and initiate transfers (services regulated by the Revised European Payment Services Directive no. 2, known as PSD2), with the customer's consent and in a totally secure manner.
The services it offers range from API (Application Program Interface) bricks to complete white-label mobile app solutions covering the needs of start-ups as well as banks and insurance companies. These solutions enable the development of new services and new sources of revenue from multiple use cases: budget management, pathways to credit grants, accounting, loyalty, etc.
Its mobile application Linxo, which is already installed and used by more than 3 million people in France, is an intelligent financial assistant, which allows everyone to have an overview of their finances and to simplify the management of their money.
The company has 85 employees, mainly in Aix-en-Provence and in the Crédit Agricole Villages in Paris and Sophia Antipolis.
WU-G
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210629005637/en/
Contact information
Media contacts:
Nicholas Mandalas
Nicholas.Mandalas@wu.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
